SBIR Phase I: SERS Enhanced Ligase Detection Reaction Chip for the Molecular Diagnosis of Cancer

SBIR 第一期：用于癌症分子诊断的 SERS 增强连接酶检测反应芯片

• 批准号: 1045381
• 负责人: Scott Stelick
• 金额: $ 15万
• 依托单位: Illuminaria, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1045381&HistoricalAwards=false
• 关键词: SBIR; Phase; SERS; Enhanced; Ligase

This Small Business Innovation Research (SBIR) Phase I project proposes to develop an entirely new platform for the molecular diagnostics of cancer exploiting a new Surface Enhanced Raman Scattering (SERS) enhanced Ligase Detection Reaction (LDR) and an optically active microfluidic chip. Since every dye has a unique Raman fingerprint, the number of single nucleotide polymorphisms (SNPs) that can be screened for in parallel is dramatically increased due to lower spectral overlap. The goal for the Phase I work is to develop a set of target-specific LDR probes in a 6-plex format that would match the current state-of-the-art. For future work, we will develop an assay for a 12-plex format that will double the number of targets that can be screened in one sample using this fluorescence-based technology. In parallel with the development of the screening reaction, we will create a novel "optofluidic" chip that addresses the challenges with on-chip Raman signal detection. The primary advantage of the proposed approach is that it avoids the fundamental limitation of the existing state-of-the-art, Real-Time Polymerase Chain Reaction, by detecting the Raman fingerprint of the dye rather than the florescence emission. The broader impact/commercial potential of this project is the ability to screen for a greater number of single nucleotide polymorphisms (SNPs) without sacrificing speed and ease-of-use, which may enable more rapid molecular diagnosis of cancer and other genetic diseases. In some cases, SNPs are biomarkers implied in the cause of cancer while in others they represent markers indicative of an increased risk of cancer. In either case, SNPs have been shown to be good biomarkers for many classes of cancer and have further been shown to correlate with various clinicopathological features of different cancer subtypes. Of the many technologies available for SNP diagnostics, Real-Time PCR (RT-PCR) is the most appropriate for clinical diagnosis in that it requires the smallest amount of physical sample and sample preparation; however, it is limited in terms of the number of SNPs that can be screened at one time. The approach we propose will potentially double the number of SNPs that can be screened in a single sample. This advantage is particularly important in cases where the biopsied sample is not homogeneous.

这个小企业创新研究（SBIR）第一阶段项目建议开发一个全新的癌症分子诊断平台，利用新的表面增强拉曼散射（SERS）增强连接酶检测反应（LDR）和光学活性微流控芯片。由于每种染料都有独特的拉曼指纹，因此可以并行筛选的单核苷酸多态性（snp）的数量由于较低的光谱重叠而显着增加。第一阶段工作的目标是开发一套针对特定目标的6路LDR探针，以匹配当前最先进的技术。对于未来的工作，我们将开发一种12 plex格式的检测方法，该方法将使用这种基于荧光的技术在一个样品中筛选的目标数量增加一倍。在开发筛选反应的同时，我们将创建一种新型的“光流”芯片，以解决片上拉曼信号检测的挑战。该方法的主要优点是，它通过检测染料的拉曼指纹而不是荧光发射，避免了现有最先进的实时聚合酶链反应的基本限制。该项目更广泛的影响/商业潜力是能够在不牺牲速度和易用性的情况下筛选更多的单核苷酸多态性（snp），这可能使癌症和其他遗传疾病的分子诊断更加快速。在某些情况下，snp是癌症原因的生物标志物，而在其他情况下，它们代表癌症风险增加的标志物。无论哪种情况，snp已被证明是许多类型癌症的良好生物标志物，并进一步被证明与不同癌症亚型的各种临床病理特征相关。在许多可用于SNP诊断的技术中，实时荧光定量PCR （RT-PCR）最适合临床诊断，因为它需要最少的物理样品和样品制备；然而，它在一次可以筛选的snp数量方面是有限的。我们提出的方法可能会使单个样本中可以筛选的snp数量增加一倍。在活检样本不均匀的情况下，这一优势尤为重要。